Sameer Ralhan - Chemours CFO, Senior Vice President Treasurer

2CU Stock  EUR 13.99  0.78  5.28%   

President

Mr. Sameer Ralhan is Chief Financial Officer, Senior Vice President, Treasurer of the Company. Since joining Chemours in November 2014, Mr. Ralhan held several positions of increasing responsibility in strategy and mergers and acquisitions, finance, and treasury. He served as Vice President, Business Finance and Treasurer from 2018 to 2019 and Vice President, Business Finance and Head of MA from 2016 to 2018. He also served as Treasurer and Head of MA from 2015 to 2016, and Head of MA from 2014 to 2015. Prior to joining Chemours, Mr. Ralhan served as a Managing Director in the Global Natural Resources Group of Goldman Sachs Co. from 2007 to 2014, where he had several assignments advising companies in the chemicals, industrials, and basic materials sectors on MA, portfolio transformations, corporate finance matters, and capital markets transactions. Mr. Ralhan also served as an associate in the investment banking group of Bank of America Securities, LLC from 2004 to 2007 since 2019.
Age 49
Tenure 7 years
Address 1007 Market Street, Wilmington, DE, United States, 19899
Phone302 773 1000
Webhttps://www.chemours.com
Ralhan began his career as a Chemical Engineer and brings chemicals industry operating experience from his time at Aspen Technology, Inc., where as an advanced process control engineer he executed process improvement and operational enhancement initiatives for several global chemical and petrochemical companies.

Chemours Management Efficiency

The company has return on total asset (ROA) of 0.0283 % which means that it generated a profit of $0.0283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6653) %, meaning that it generated substantial loss on money invested by shareholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. The Chemours' current Other Current Assets is estimated to increase to about 85.7 M, while Total Assets are projected to decrease to roughly 7.8 B.
Chemours Co has accumulated 54 M in total debt with debt to equity ratio (D/E) of 548.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Chemours has a current ratio of 1.92, which is within standard range for the sector. Debt can assist Chemours until it has trouble settling it off, either with new capital or with free cash flow. So, Chemours' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Chemours sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Chemours to invest in growth at high rates of return. When we think about Chemours' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Zhiheng WangAgricultural Bank of
53
Fanjun MengAgricultural Bank of
53
Andrew WattStrategic Education
48
Scott LilesDeVry Education Group
60
Joe SchaeferStrategic Education
N/A
Bryan KnutsonTITAN MACHINERY
40
Daniel JacksonStrategic Education
51
Wanjun FuAgricultural Bank of
55
F SmithConstruction Partners
50
Sondra StallardStrategic Education
76
Dajun WangAgricultural Bank of
51
Nuno FernandesAmerican Public Education
49
Con WadsworthSterling Construction
65
Wenjin WangAgricultural Bank of
54
R PalmerConstruction Partners
66
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. CHEMOURS operates under Specialty Chemicals classification in Germany and is traded on Frankfurt Stock Exchange. It employs 7000 people. Chemours Co (2CU) is traded on Frankfurt Exchange in Germany and employs 6,000 people. Chemours is listed under Specialty Chemicals category by Fama And French industry classification.

Management Performance

Chemours Leadership Team

Elected by the shareholders, the Chemours' board of directors comprises two types of representatives: Chemours inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemours. The board's role is to monitor Chemours' management team and ensure that shareholders' interests are well served. Chemours' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemours' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonathan Lock, Sr Officer
Amber Wellman, Chief Officer
Kurt Bonner, Ma Relations
David Will, Controller Officer
Kristine Wellman, General VP
Sameer Ralhan, CFO, Senior Vice President Treasurer
Shane CPA, Senior CFO
Brandon Ontjes, Vice Relations
Camela Wisel, Chief VP
Denise Dignam, CEO President
Mark Newman, CFO, Senior Vice President
Aditya Beri, Interim Business
Matthew Conti, Chief Officer
Edwin Sparks, President - Chemical Solutions
Alisha Bellezza, Director of Investor Relations
Joseph Martinko, President Solutions
Susan Kelliher, Senior Vice President – Human Resources and Health Services
Alvenia Scarborough, Sr Officer
Gerardo Calderon, President Materials

Chemours Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemours a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Chemours offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemours' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemours Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemours Co Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Understanding that Chemours' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Chemours represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Chemours' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.